Suling Liu, Ph.D.

Education

• Ph.D. in Molecular and Cellular Biology, The Ohio State University, Columbus, OH, USA                                   

• B.S. in Biology, University of Science and Technology of China, Hefei, Anhui, China

Work experience

• Dec. 2016~Present, Professor, Shanghai Cancer Hospital, Institutes of Biomedical Sciences, Fudan University, Shanghai, China

• Nov. 2012~Nov. 2016, Professor, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui, China

• Oct. 2010~Oct. 2012, Research Assistant Professor, Department of Internal Medicine / Comprehensive Cancer Center, University of Michigan, Ann Arbor, USA.

• Oct. 2006~Oct. 2010, Research Investigator, Department of Internal Medicine / Comprehensive Cancer Center, University of Michigan, Ann Arbor, USA.

• Oct. 2003~Sept. 2006, Research Fellow, Department of Internal Medicine / Comprehensive Cancer Center, University of Michigan, Ann Arbor, USA.

Contact

Institutes of Biomedical Sciences, Fudan University, Shanghai 200032 Tel: 021-34771023 (Lab), 021-34774409 (Office)

Email: suling@fudan.edu.cn

Biography

Dr. Suling Liu is currently a professor at Fudan University Cancer Hospital and Institutes of Biomedical Sciences. Dr. Liu's research has focused on characterization and regulation mechanisms of normal and malignant breast stem cells. Evidence from this research is of obvious significance for the development of new diagnosis tools and innovative treatments for breast cancer. After getting PhD from Ohio State University, her research interest on breast carcinogenesis took her to focus on cancer therapy to find novel treatments to cancer by targeting the cancer stem cells. In the past, she has been studying breast cancer stem cell heterogeneity and the interplay with tumor microenvironment. In recent five years, as a corresponding or co-corresponding author, Dr. Liu has published 29 research articles in Nature Cell Biology, Advanced Science, Nature Communications, Science Advances, Cancer Research, Clinical Cancer Res, Plos Biology and other famous SCI Journals (total over 91 publications which has been cited over 18000 times).

Research Areas and Research interest

1. The Regulation and drug resistance of heterogeneous breast cancer stem cells； 
2. The origin of breast cancer stem cells； 
3. The interaction of breast cancer stem cells and tumor microenvironment； 
4. The immune-regulation of breast cancer stem cells； 
5. The development of potential therapeutic approaches and drugs to target breast cancer stem cells.

Selected Publications

1. Dong, H., Zhang, L.*, Liu, S.*. Targeting HMGB1: An available Therapeutic Strategy for Breast Cancer Therapy. International journal of biological sciences 18(8):3421-3434，2022.

2. Sheng, D., Ma, W., Zhang, R., Zhou, L., Deng, Q., Tu, J., Chen, W., Zhang, F., Gao, N., Dong, M., Wang, D., Li, F., Liu, Y., He, X., Duan, S., Zhang, L., Liu, T.*, Liu, S.*. Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization. Journal for ImmunoTherapy of Cancer 10(5):e003793, 2022.

3. Zhang, R.#, Tu, J.#, Liu ca, S.*.  Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity. Seminars in Cancer Biology 82:11-25, 2022. PMID: 33737107

4. Xu, J., Yang, X., Deng, Q., Yang, C., Wang, D., Jiang, G., Yao, X., He, X., Ding, J., Qiang, J., Tu, J., Zhang, R., Lei, Q., Shao, Z-M., Bian, X.*, Hu, R.*, Zhang, L.*, Liu, S.*. TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer. Nature Communications 12(1):4413, 2021. PMID: 34285210

5. Liu, C., Qiang, J., Deng, Q., Xia, J., Deng, L., Zhou, L., Wang, D., He, X., Liu, Y., Zhao, B., Lv, J., Yu, Z., Lei, Q., Shao, Z.*, Zhang, X.*, Zhang, L.*, Liu, S.*  ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression. Cancer Research 81(23):5919-5934, 2021. PMID: 34580061

6. Jiang, G.#, Tu, J.#, Zhou, L.#, Dong, M., Fan, J., Chang, Z., Zhang, L., Bian, X., Liu, S.* Single-cell transcriptomics reveal the heterogeneity and dynamic of cancer stem-like cells during breast tumor progression. Cell Death and Disease 12(11):979, 2021. 

7. Huang, Y.#, Wang, H., Hao, Y., Lin, H., Dong, M., Ye, J., Song, L., Wang, Y., Li, Q., Shan, B., Jiang, Y., Li, H., Shao, Z.M., Kroemer, G., Zhang, H., Bai, L., Jin, T., Wang, C., Ma, Y., Cai, Y., Ding, C., Liu, S.*, Pan, Y.*, Jiang, W.*, Zhou R.*. Myeloid PTEN promotes chemotherapy -induced NLRP3-inflammasome activation and antitumour immunity. Nature Cell Biology 22(6):716-727, 2020. PMID:32367047

8. Qin, Y. #, Chen, W. #, Jiang, G., Zhou, L., Yang, X., Li, H., He, X., Wang, H., Zhou, Y., Huang, S., Liu, S.*. Interfering MSN-NONO complex activated CREB signaling serves a novel therapeutic strategy for triple-negative breast cancer, Science Advances 6(8)：eaaw9960, 2020.PMID: 32128390.

9. Zhang, L. #, Qiang, J. #, Yang, L. #, Wang, D., Adeel, R., He, X., Chen, W., Sheng , D., Zhou, L., Jiang, Y. Z., Li, T., Du, Y., Feng, J., Hu, X., Zhang, J., Hu, X. C., Shao, Z. M., Liu, S.*. IL1R2 blockade suppresses breast tumorigenesis and progression by impairing USP15-dependent BMI1 stability. Advanced Science 7(1):1901728, 2020. PMID: 31921558

10. Zhang, J., Yang, Y., Zhou, S., He, X., Cao, X., Wu, C., Hu, H., Qin, J., Wei, G., Wang, H., Liu, S.*, Sun, L.*. Membrane-bound TNF mediates microtubule-targeting chemotherapeutics-induced cancer cytolysis via juxtacrine inter-cancer-cell death signaling. Cell Death and Differentiation 27(5):1569-1587, 2019. PMID: 31645676

11. Liu, B., Du, R., Zhou L., Xu, J., Chen, S., Chen, J., Yang, X., Liu, D-X., Shao, Z-M., Zhang, L., Yu, Z., Xie, N. *, Guan, J-L.*, and Liu, S.*. miR-200c/141 regulates breast cancer stem cell heterogeneity via targeting HIPK1/β-catenin axis. Theranostics 8(21):5801-5813, 2018. PMID: 30613263

12. Deng, L., Gao, X., Liu, B., He, X., Xu, J., Qiang, J., Wu, Q., Liu, S.*. NMT1 inhibition modulates breast cancer progression through stress-triggered JNK pathway. Cell Death and Disease 9(12):1143, 2018. PMID: 30446635

13. Chen, W., Qin, Y., Wang, D., Zhou, L., Liu, Y., Chen, S., Yin, L., Xiao, Y., Yao, X-H., Yang, X., Ma, W., Chen, W., He, X., Zhang, L., Yang, Q., Bian, X., Shao, Z-M., Liu, S.* CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. Plos Biology 16(7):e2005869, 2018. PMID: 30052635

14. Liu, M., Liu, Y., Deng, L., Wang, D., He, X., Zhou, L., Wicha, M.S., Bai, F.*, Liu, S.*.Transcriptional profiles of different states of cancer stem cells in triple-negative breast cancer. Mol Cancer 17(1):65, 2018. PMID: 29471829

15. Du, R., Liu, B., Zhou, L., Wang, D., He, X., Xu, X., Zhang, L., Niu, C.*, Liu, S.*. Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer. Cell Death and Disease 9(2):126, 2018. PMID: 29374148

16. Wang, D., Xu, J., Liu, B., He, X., Zhou, L., Hu, X., Qiao, F., Zhang, A., Xu, X., Zhang, H., Wicha, MS., Zhang, L., Shao, Z., Liu, S.*. IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing breast cancer. Cell Death and Differentiation 25(2):330-339, 2018. PMID: 29027990

17. Zhou, L., Sheng, D., Deng, Q., Wang, D., Liu, S.*. Development of a novel method for rapid cloning of shRNA vectors, which successfully knocked down CD44 in mesenchymal-like triple negative breast cancer cells. Cancer Communications 38(1):57, 2018. PMID: 30249304

18. Zhou, L., Sheng, D., Wang, D., Ma, W., Deng, Q., Deng, L., Liu, S.*. Identification of cancer-type specific expression patterns for active aldehyde dehydrogenase (ALDH) isoforms in ALDEFLUOR assay. Cell Biol Toxicol (online) 2018. PMID: 30220009

19. Liu, Y., Burness, M.L.*, Martin-Trevino, R., Guy, J., Bai, S., Harouaka, R., Brooks, M.D., Shang, L., Fox, A., Luther, T.K., Davis, A., Baker, T.L., Colacino, J., Clouthier, S.G., Shao, Z-M., Wicha, M.S., and Liu, S*. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer. Clinical Cancer Research 23(2): 514-522, 2017.